CKCynthia Kretschmar

Cynthia Kretschmar

*This is an algorithmically generated author record based on publicly available information.

Cynthia Kretschmar has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Kevin Murray

    ‡Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI

    2 shared publications
  • Morris Kletzel

    Department of Hematology/Oncology/Transplantation, Children’s Memorial Hospital, Chicago, IL

    2 shared publications
  • Robert Castleberry

    Department of Pediatrics, Children’s Hospital of Alabama, Birmingham, AL

    2 shared publications
  • Robert Marcus

    †Department of Radiation Oncology, Mercy Medical Center, Cedar Rapids, IA

    2 shared publications
  • Wendy B. London

    Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL

    2 shared publications
  • E. Ide Smith

    1 shared publication

Latest Publications

  • Outcomes of the POG 9340/9341/9342 trials for children with high‐risk neuroblastoma: A report from the Children's Oncology Group

    by Peter E. Zage, Morris Kletzel, Kevin Murray, Robert Marcus, Robert Castleberry, Yang Zhang, Wendy B. London, Cynthia Kretschmar

    Background: From 1993 to 1995, the Pediatric Oncology Group (POG) enrolled patients with high‐risk neuroblastoma on three sequential, conjoined studies: a phase II induction window (9340), followed by intensive multiagent induction chemotherapy (9341), and subsequent myeloablative therapy with autologous stem cell rescue (9342). We report here the outcomes of patients treated on these studies.Patients and Methods: Patients were between 1 and 21 years old with high‐risk neuroblastoma. Phase II window therapy consisted of two courses of either paclitaxel, topotecan, or cyclophosphamide with topotecan. Induction therapy consisted of at least five cycles of intensive chemotherapy, followed by myeloablative therapy with purged autologous stem cell reinfusion. Patient responses, treatment toxicities, and overall and event‐free survival rates were calculated.Results: Eighty‐four percent of patients responded to induction chemotherapy, with 39% achieving complete response. Toxicities were primarily hematologic. The 7‐year EFS and OS rates for all eligible patients on POG 9341 were 23 ± 4% and 28 ± 4%, respectively. The 7‐year EFS and OS rates for patients treated on POG 9342 were 27 ± 6% and 29 ± 6%, respectively.Conclusions: These studies were the first attempt by POG to use autologous stem cell transplantation for neuroblastoma treatment in a cooperative group setting. Toxicities and outcomes were comparable to contemporary cooperative group studies. The phase II induction window had no detectable effect on outcomes. New strategies are needed to improve survival for this devastating disease. Pediatr Blood Cancer 2008;51:747–753.


  • Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group

    by C. Kretschmar, L. Kleinberg, M. Greenberg, P. Burger, Emi Holmes, M. Wharam

    Background: This Phase II study was designed to determine response to chemotherapy and survival after response‐based radiation (RT) in children with CNS germ cell tumors.Procedure: Children with germinomas and normal markers received cisplatin 100 mg/m2 + etoposide, alternating with vincristine + cyclophosphamide (CPM) 2 g/m2/d, for four cycles. Children with nongerminomatous tumors or with abnormal markers received doubled doses of cisplatin and CPM. For germinoma patients in complete response (CR), RT was decreased from 50.4 to 30.6 Gy. High‐risk patients received neuraxis RT: 50.4 Gy local + 30.6 Gy neuraxis in CR; 54 Gy local + 36 Gy if less than CR.Results: Of 12 germinoma patients, 4 had cerebrospinal fluid (CSF) human chorionic gonadotropin (HCG) 6.9–21 mIU/ml. Of 14 nongerminomatous patients, HCG in serum or CSF was >50 mIU/ml in 9, α‐fetoprotein (AFP) abnormal in 9. Four germinoma patients attained CR, six PR, one SD, one not evaluable after resection. Two nongerminomatous patients had CR, three PR, three SD, one PD, four not evaluable after resection; one inadequately treated patient had progressive disease (PD). Both PD patients died; one SD patient died during a seizure. Eleven germinoma patients are PF at median 66 months; one patient in CR refused RT, had PD at 10 months, received RT, and was PF at 56 months. Eleven of 14 nongerminomatous patients were PF at median 58 months.Conclusion: Response (germinoma, 91%; nongerminomatous, 55%) and survival are encouraging after this regimen plus response‐based RT. Pediatr Blood Cancer 2007;48:285–291.


  • Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study

    by Cynthia S. Kretschmar, Morris Kletzel, Kevin Murray, Paul Thorner, Vijay Joshi, Robert Marcus, E. Ide Smith, Wendy B. London, Robert Castleberry

    Purpose: Most children older than 1 year of age with metastatic neuroblastoma (NB) die despite intensive chemotherapy and bone marrow transplantation. The Pediatric Oncology Group conducted a study of paclitaxel, topotecan, and topotecan-cyclophosphamide (topo-cyclo) in newly diagnosed children with stage IV NB. Patients and Methods: There were 102 patients enrolled between September 1993 and October 1995; two of them were later shown to be ineligible. Of the remaining 100 patients, the first cohort of 33 patients received paclitaxel 350 mg/m2 intravenously (IV) over 24 hours every 14 to 21 days; the next 33 patients received topotecan 2 mg/m2/d for 5 days IV every 21 days; a third cohort of 34 patients were treated with IV cyclophosphamide 250 mg/m2 followed by topotecan 0.75 mg/m2 each day for 5 days every 21 days. Patients were re-evaluated after two courses and then treated with intensive induction therapy and bone marrow transplantation. Results: Objective responses (complete response + partial response + mixed response) were documented in 67% of children who received topotecan, 76% after topo-cyclo, and 25% after paclitaxel. Four patients had grade 3 to 4 allergic reactions to paclitaxel; most patients developed grade 3 to 4 marrow suppression after topotecan or topo-cyclo. Neither disease-free survival nor overall survival differed significantly between children who received a phase II agent and those who did not. The 6-year disease-free survival and overall survival rates for all 100 children were 18% ± 5% and 26% ± 5%, respectively. Conclusion: Topotecan and topo-cyclo are active in children with NB, are well tolerated, and should be evaluated further in combination regimens.